Immunotherapy Approved for Platinum-resistant Gynecologic Cancers
Pembrolizumab plus paclitaxel, with or without bevacizumab, was approved for PD-L1-positive ovarian, fallopian tube, and peritoneal cancers. The U.S....
Progress Against Cancer
Pembrolizumab plus paclitaxel, with or without bevacizumab, was approved for PD-L1-positive ovarian, fallopian tube, and peritoneal cancers. The U.S....
The FDA has approved daratumumab and hyaluronidase-fihj in combination with other therapies as first-line treatment for certain patients with...
Patients now have the option of receiving the bispecific antibody amivantamab as an injection. The U.S. Food and Drug...
The FDA has converted the accelerated approval of rucaparib to full approval for certain patients with metastatic castration-resistant prostate...
Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration...
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent plus a corticosteroid for...
Lisocabtagene maraleucel was granted approval for adults with treatment-resistant marginal zone lymphoma. The U.S. Food and Drug Administration (FDA)...
Pirtobrutinib was approved for certain relapsed/refractory chronic lymphocytic leukemias or small lymphocytic lymphomas. The U.S. Food and Drug Administration...
Durvalumab was approved as neoadjuvant and adjuvant treatment with chemotherapy for resectable gastric or gastroesophageal junction cancer. The U.S....
The combination therapy is approved for pre- and post-surgery bladder cancer treatment. The U.S. Food and Drug Administration (FDA)...